Home » Affymax Rises on FDA Drug Review
Affymax Rises on FDA Drug Review
The U.S. Food and Drug Administration raised safety concerns about Affymax’s anemia drug but the agency’s criticisms were more muted than investors expected, sending Affymax shares higher in early trading.
The Street
The Street
Upcoming Events
-
02May
-
07May
-
14May
-
23May
-
30May